Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganciclovir in Refractory Moderate-to-severe Allergic Rhinitis
NCT06436534Recruiting
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial in allergic rhinitis (AR) comparing Ganciclovir with Placebo (2 arms). Primary endpoint: Rate of improvement in Total Nasal Symptom Score at 2 weeks. Started May 2024; status: recruiting.
02
Drugs
ganciclovir
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06436534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436534.